References
- Kutlar A, Embury SH. Cellular adhesion and the endothelium: p-selectin. Hematol Oncol Clin North Am. 2014;28(2):323–339.
- André P. P-selectin in haemostasis. Br J Haematol. 2004;126(3):298–306.
- Kappelmayer J, Nagy B Jr., Miszti-Blasius K, et al. The emerging value of P-selectin as a disease marker. Clin Chem Lab Med. 2004;42(5):475–486.
- Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439.
- Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.
- Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018–2031.
- Schmitt C, Abt M, Ciorciaro C, et al. First-in-man study with inclacumab, a human monoclonal antibody against P-selectin. J Cardiovasc Pharmacol. 2015;65(6):611–619.
- Geng X, Mihaila R, Yuan Y, et al. Inclacumab, a fully human anti-P-selectin antibody, directly binds to PSGL-1 binding region and demonstrates robust and durable inhibition of cell adhesion. Presented at: American Society of Hematology Annual Meeting & Exposition; 2020 Dec 5–8; virtual. Poster 1707.
- Mayer C, Cooper DS, Redfern A, et al. Preliminary results of a phase 1 study in healthy subjects administered inclacumab, a fully human IgG4 anti-P-selectin monoclonal antibody in development for treatment of sickle cell disease. Presented at: American Society of Hematology Annual Meeting & Exposition; 2021 Dec 11; Atlanta, GA, USA, and virtual. Poster 977.
- Adakveo. Prescribing information. Novartis Pharmaceuticals Corporation. 2021.
- Adakveo. Summary of product characteristics. Novartis Pharmaceuticals Corporation. 2020.
- Hanson QM, Barb AW. A perspective on the structure and receptor binding properties of immunoglobulin G Fc. Biochemistry. 2015;54(19):2931–2942.
- Oganesyan V, Gao C, Shirinian L, et al. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr. 2008;64(Pt 6):700–704.
- GBT provides regulatory and pipeline updates in sickle cell disease (SCD) [Internet]. South San Francisco CA: GBT; 2021 Jul 22 cited Oct 15, 2021]. Available from 2021 Oct 15: https://ir.gbt.com/news-releases/news-release-details/gbt-provides-regulatory-and-pipeline-updates-sickle-cell-disease
- Morrison M, Palermo G, Schmitt C. Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2015;71(11):1365–1374.
- Tardif JC, Tanguay JF, Wright SR, et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol. 2013;61(20):2048–2055.
- A study of a single dose of inclacumab to reduce re-admission in participants with sickle cell disease and recurrent vaso-occlusive crises: clinicalTrials.gov identifier: NCT04927247; [updated 2021 November 2; cited 2021 December 3]. Available from 2021 Jun 15: https://clinicaltrials.gov/ct2/show/NCT04927247
- A study to assess the safety and efficacy of inclacumab in participants with sickle cell disease experiencing vaso-occlusive crises: clinicalTrials.gov identifier: NCT04935879; [updated 2021 November 5; cited 2021 December 3]. Available from 2021 Jun 23: https://clinicaltrials.gov/ct2/show/NCT04935879
- Ambrogelly A, Gozo S, Katiyar A, et al., Analytical comparability study of recombinant monoclonal antibody therapeutics. MAbs. 2018. 10(4): 513–538.
- GBT expands sickle cell disease pipeline with worldwide licensing agreement for inclacumab for the treatment of vaso-occlusive crisis [Internet]. South San Francisco CA: GBT; 2018 Aug 23 cited 2021 Dec 2]. Available from 2021 Dec 2: https://ir.gbt.com/news-releases/news-release-details/gbt-expands-sickle-cell-disease-pipeline-worldwide-licensing
- ICH Q5E: comparability of biotechnological/biological products subject to changes in their manufacturing process 2005 cited 2021 Dec 2]. Available from 2021 Dec 2: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-5-e-comparability-biotechnological/biological-products-step-5_en.pdf
- Guideline on development, Production, characterisation and specification for monoclonal antibodies and related products; EMA/CHMP/BWP/532517/2008 2016 cited 2021 Dec 2]. Available from 2021 Dec 2: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-production-characterisation-specification-monoclonal-antibodies-related_en.pdf
- Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process. Non-clinical and clinical issues; EMEA/CHMP/BMWP/101695/2006 2007 cited 2021 Dec 2]. Available from 2021 Dec 2: https://www.ema.europa.eu/documents/scientific-guideline/guideline-comparability-biotechnology-derived-medicinal-products-after-change-manufacturing-process_en.pdf
- Center for Drug Evaluation and Research. Guidance for Industry. Statistical Approaches to Establishing Bioequivalence 2001 cited 2022 Oct 26]. Available from 2022 Oct 26: https://www.fda.gov/media/70958/download
- ICH Q6B: specifications: test procedures and acceptance criteria for biotechnological/biological products: ICH; 1999 cited 2021 Dec 3]. Available from 2021 Dec 3: https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf
- Bas M, Terrier A, Jacque E, et al. Fc sialylation prolongs serum half-life of therapeutic antibodies. J Immunol. 2019;202(5):1582–1594.
- Ghaderi D, Taylor RE, Padler-Karavani V, et al. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol. 2010;28(8):863–867.
- Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733–26740.